SLIDE 1 The 2016 Access to Medicine Index Breakfast Meeting
Jayasree K. Iyer, Executive Director, ATM Foundation 24th November 2016 HGPI, Tokyo
SLIDE 2 5 billion people have access to medicine
2 billion to go
Availability Accessibility Affordability Acceptability
SLIDE 3 The Access to Medicine Foundation
- Research on, and incentives for, pharmaceutical
companies and access to medicine
- Independent, non-profit organisation
- Multi-stakeholder approach
SLIDE 4 Bu Build consensus
- n what to expect from the industry and
where incentives and disincentives exist.
St Stim imula ulate a a “rac ace to do do well” ll”
in key access-to-medicine areas, by creating competition on targets and topics.
Di Diffu fuse best practices
to share information and new insights into the best approaches for driving change.
Our model for change
SLIDE 5
What we do
SLIDE 6
SLIDE 7
60 investors – AUM in excess of USD 5.5 trillion
SLIDE 8
2016 Access to Medicine Index What we measure
SLIDE 9
Framework for analysis
SLIDE 10 AbbVie Inc. Astellas Pharma Inc. AstraZeneca plc Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Co. Daiichi Sankyo Co. Ltd. Eisai Co. Ltd. Eli Lilly & Co. Gilead Sciences Inc. GlaxoSmithKline plc Johnson & Johnson Merck & Co. Inc. Merck KGaA Novartis AG Novo Nordisk A/S Pfizer Inc. Roche Holding AG Sanofi Takeda Pharmaceutical
Company scope
SLIDE 11
Geographic scope
SLIDE 12
Disease scope
SLIDE 13
2016 Access to Medicine Index Report Highlights
SLIDE 14
A comprehensive report
SLIDE 15
2016 Access to Medicine Index Key Finding: R&D
SLIDE 16
Leaders in R&D address needs and ensure access for people living in low- and middle-income countries
SLIDE 17
Efforts to meet product R&D needs are uneven
SLIDE 18
Efforts to meet product R&D needs are uneven
SLIDE 19
Over one third of product gaps with low commercial incentive being addressed Over one third of product gaps with low commercial incentive being addressed
SLIDE 20
Over one third of product gaps with low commercial incentive being addressed Over one third of product gaps with low commercial incentive being addressed
SLIDE 21
Collaborative research models appear effective in engaging the industry in developing urgently needed products with low commercial potential
SLIDE 22
Seven companies have the strongest focus on high-priority product gaps with low commercial incentive
SLIDE 23
Only a few commercially-promising projects have plans for access in place
SLIDE 24
Access provisions are set earlier when projects are conducted in partnership
SLIDE 25
2016 Access to Medicine Index Key Finding: Capacity Building
SLIDE 26
Leading companies systematically address local needs
SLIDE 27
Leading companies systematically address local needs
SLIDE 28
2016 Access to Medicine Index Key Finding: Business Models
SLIDE 29
Commercial business models address lower income populations
SLIDE 30
Commercial business models address lower income populations
SLIDE 31
2016 Access to Medicine Index Key Finding: Product Deployment
SLIDE 32
True needs-based pricing is limited
SLIDE 33
Leaders take multiple socio-economic factors into account when pricing their products
SLIDE 34
Licensing expands but excludes key middle-income countries
SLIDE 35 Large emerging markets are often
- verlooked in voluntary licensing
agreements
SLIDE 36
2016 Access to Medicine Index Performance of Japanese Companies
SLIDE 37
SLIDE 38 Eisai Co., Ltd.
Influence & Compliance
R&D through partnerships, notably NTDs
enforcing patents in certain low-and middle income countries
Lymphatic Filariasis
SLIDE 39 Takeda Co., Ltd.
launched
(leishmaniasis, Chagas), dengue and norovirus
enforcing patents in Sub-Saharan Africa
SLIDE 40 Daiichi Sankyo Co., Ltd.
for multiple discovery projects
falsified medicine to national authorities
clinics, access to medical services
vaccines in India, Cameroon and Tanzania
SLIDE 41
diseases such as schistosomiasis and Chagas disease
management in China and South East Asia
manufacturing capacity in Brazil and Iran
Astellas Pharma Inc.
SLIDE 42
Q & A
SLIDE 43 Thank you
jiyer@atmindex.org www.accesstomedicineindex.org
